Business, energy, technology, markets and global industry news from Business News Today

Dr. Reddy’s Laboratories

PharmaDeviceNews Dr. Reddy’s Laboratories
Gilead Sciences is preparing generic manufacturing for investigational once-yearly lenacapavir across 120 countries before the Phase 3 PURPOSE 365 HIV prevention study reports. Representative image.
Features & Analysis

Gilead is licensing once-yearly lenacapavir before Phase 3 results. Why take the manufacturing risk now?

Gilead Sciences has expanded royalty-free licensing agreements with six generic manufacturers to cover investigational once-yearly lenacapavir for HIV prevention while the Phase 3 PURPOSE 365 study is still underway. The decision deliberately moves manufacturing and access planning ahead of regulatory certainty, potentially shortening the years-long delay that has historically separated pharmaceutical innovation from broad availability

Read More
Representative image: Immutep refocuses eftilagimod alfa development after TACTI-004, targeting head and neck cancer and soft tissue sarcoma.
Pharma & Biotech

Efti gets a new development path as Immutep investigates manufacturing link to Phase III setback

Immutep finds manufacturing differences after TACTI-004 and refocuses efti on head and neck cancer and sarcoma. See what comes next.

Read More
Pharma & Biotech

Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval

Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.

Read More
Representative image: Generic semaglutide injection pens on a clinical desk with Canadian healthcare cues, reflecting Dr. Reddy’s Laboratories’ launch of generic semaglutide injection in Canada and the growing focus on GLP-1 access for type 2 diabetes treatment.
Pharma & Biotech

Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?

GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.

Read More
Representative image: Generic semaglutide injection pens and diabetes-care materials illustrate Apotex’s Health Canada approval for Apo-Semaglutide Injection, a generic Ozempic equivalent that could reshape GLP-1 access and diabetes treatment affordability in Canada.
Pharma & Biotech

Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market

Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.

Read More
Pharma & Biotech

What the Nexus Pharmaceuticals cyclophosphamide launch reveals about competition in sterile generic oncology drugs

Nexus Pharmaceuticals has launched cyclophosphamide injection in ready-to-dilute vials. Read what this means for oncology workflows and generic drug access.

Read More
Pharma & Biotech

Allergy relief shake-up: Dr. Reddy’s launches generic Pataday 0.7% eye drops

Dr. Reddy’s launches first U.S. generic of Pataday 0.7% eye drops. Find out what this means for the OTC allergy market and Novartis’s branded edge.

Read More
Pharma & Biotech

Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance

Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.

Read More